Related Experiment Videos
[Hypofibrinolysis and thrombophilia].
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1984
Summary
1-deamino-8-D-arginine vasopressin (DDAVP) effectively assesses fibrinolytic capacity, revealing reduced capacity in idiopathic venous thrombosis and myocardial infarction patients. DDAVP is superior to venous occlusion for this assessment.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Context:
- Assessing fibrinolytic capacity is crucial for understanding thrombotic disorders.
- Venous occlusion and 1-deamino-8-D-arginine vasopressin (DDAVP) are established methods for evaluating fibrinolysis.
- Idiopathic venous thrombosis and myocardial infarction are associated with altered fibrinolytic function.
Purpose:
- To compare the efficacy of DDAVP and venous occlusion in assessing fibrinolytic capacity.
- To evaluate fibrinolytic capacity in healthy subjects and patients with non-idiopathic venous thrombosis, idiopathic venous thrombosis, and myocardial infarction.
Summary:
- 1-deamino-8-D-arginine vasopressin (DDAVP) administration revealed reduced fibrinolytic capacity in 5/8 patients with idiopathic venous thrombosis and 4/8 with myocardial infarction.
- Healthy subjects and patients with non-idiopathic venous thrombosis showed no significant changes in fibrinolytic capacity with either method.
- DDAVP proved to be a more sensitive stimulus than venous occlusion for detecting impaired fibrinolytic capacity.
Impact:
- DDAVP is a superior diagnostic tool for identifying fibrinolytic deficits in thrombotic conditions.
- Findings may guide therapeutic strategies for patients with idiopathic venous thrombosis and myocardial infarction.
- This study enhances the understanding of fibrinolysis in various cardiovascular and hematological diseases.